Independent data monitoring committees help to ensure patient safety and uphold trial integrity. In Central Nervous System (CNS) studies, independent data monitoring is especially critical due to challenges such as patient enrollment, rater variability, and placebo response rates. The right DMC provider can help overcome these challenges and optimize the clinical research approach.
The following case study illustrates how a clinical-stage biotechnology company developing novel medicines to address CNS diseases was concerned about the management and assessment of their study data. To navigate this critical phase, the biotech selected Axio, a Cytel company, as an independent statistical center to provide DMC support for their ongoing studies.
Download the case study below to learn how partnering with Axio enabled the client to expedite their DMC safety reports, all while maintaining the highest standards of patient safety and trial integrity.
Our IDMC case study is featured as part of our winter Weekend Reads series, which includes complimentary publications on a variety of topics on clinical trial design and data science. Subscribe to our weekly newsletter below and never miss a post!
Read more from Perspectives on Enquiry and Evidence:
Sorry no results please clear the filters and try again
Preserving Trial Integrity After Receiving an Unanticipated IDMC Recommendation
Conduct of IDMCs for Cell and Gene Therapy Trials
Reducing Independent Data Monitoring Committee Timelines: A Focus on Formal Interim Analyses
